Second Affiliated Hospital, Zhejiang University, School of Medicine
With
GeneCast Biotechnology Co., Ltd.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient is ≥ 18 years-old at the time of consent to participate this trial
Patients with stage I-III invasive breast cancer
No prior anti-cancer treatment
Felt to be a possible candidate for neoadjuvant therapy by their physician
You may not be if
Known to have other aggressive malignant tumor in the past 5 years.
Breast cancer during lactation; Inflammatory breast cancer; Acute inflammatory disease, pregnancy and other conditions may affect the levels of ctDNA and/or peripheral inflammatory indicators.
There are other concomitant diseases that seriously threaten the patient's safety or affect the patient's completion of the study, such as serious infection, liver disease, cardiovascular disease, kidney disease, respiratory disease or uncontrolled diabetes or dyslipidemia.
The investigator determines that subjects are not appropriate to participate in the study due to other factors.
Clareo Health | Circulating Tumor DNA Monitoring in Breast Cancer Undergoing Neoadjuvant Therapy
